National Pharmacy Health & Leadership Alliance Verify a MemberMember Login

NPHLA Trackers

Trackers

Evergreen reference trackers built from official records — clinical trials, verified regulatory dates and FDA shortage, recall and clearance records. Every row links to its primary source, with methodology, coverage and limitations stated.

All trackers

6 trackers
  • GLP-1 & obesity drug pipeline (ClinicalTrials.gov)

    GLP-1 & Obesity Drug Pipeline

    Phase 2 and phase 3 clinical trials of GLP-1, amylin and other incretin-based obesity and metabolic medicines registered on ClinicalTrials.gov, with each study’s phase, recruitment status, sponsor and latest registry update.

    Records
    82
    Changed in 7 days
    0
    Latest record
    • Pending editorial review
  • Clinical trials (ClinicalTrials.gov)

    Clinical Trial Tracker: Metabolic & Aesthetic Medicine

    Clinical trials followed in metabolic and aesthetic medicine — obesity and incretin therapies, neurotoxins, dermal fillers, regenerative treatments and hair restoration — with each study’s status, phase and latest registry update.

    Records
    187
    Changed in 7 days
    0
    Latest record
    • Pending editorial review
  • Regulatory deadline calendar (verified dates)

    Regulatory Deadline Calendar

    Verified public-comment deadlines and effective dates from Federal Register documents on the pharmacy, compounding, telehealth, privacy and benefit topics we track — upcoming dates first, then dates that passed in the last 30 days.

    Records
    4
    Changed in 7 days
    0
    Latest record
    • Pending editorial review
  • Drug shortage monitor (FDA)

    GLP-1 Drug Shortage Monitor

    FDA drug-shortage status for semaglutide, tirzepatide and liraglutide products, package by package, as published in FDA’s drug shortage data — with every status change recorded since tracking began.

    Records
    13
    Changed in 7 days
    0
    Latest record
    • Pending editorial review
  • Compounding regulatory tracker (Federal Register / FDA)

    Compounding Regulatory Tracker

    Official federal records on drug compounding — Federal Register rules, proposed rules and notices, FDA announcements and safety alerts, and FDA enforcement-report recalls — tagged to 503A, 503B, GLP-1 compounding, USP standards, peptides and enforcement.

    Records
    54
    Changed in 7 days
    2
    Latest record
    • Pending editorial review
  • Aesthetic device clearances (FDA 510(k))

    Aesthetic Device Clearances (FDA 510(k))

    FDA 510(k) clearance decisions for energy-based and other aesthetic devices — microneedling, radiofrequency, intense pulsed light, hair removal, body contouring, skin resurfacing and cryolipolysis — with the applicant, product code and decision date.

    Records
    20
    Changed in 7 days
    0
    Latest record
    • Pending editorial review

How do the trackers work?

Each tracker is a standing view of official records that the NPHLA Intelligence pipeline already monitors. Every row carries its provenance: the source and source type, jurisdiction, the record’s own date, when it was last checked and whether that check was automated or made by an editor, the date we last updated it, its status as the source states it, and a link to the primary source.

System checked means an automated check of the official sources ran; it is not a human review. Editorially reviewed appears only when an editor has reviewed the tracker. Each tracker explains its methodology, coverage, limitations and update frequency, and offers CSV and JSON downloads of the same public information.

Trackers are professional reference tools, not medical, legal or regulatory advice. Always confirm a record in its primary source before acting on it.

Professional glossary